Abstract: The compositions and methods of this invention relate to peelable film-forming compositions that may be applied to and removed from the skin containing polyvinyl alcohols and adhesion-enhancing polymers.
Type:
Application
Filed:
April 28, 2014
Publication date:
September 11, 2014
Applicant:
JOHNSON & JOHNSON CONSUMER COMPANIES, INC.
Inventors:
Prashant Bahadur, Jeffrey M. Wu, Kamesh R. Yerramilli
Abstract: A skin disinfectant in ready-to-use concentrated liquid or dry powdered form. Ready-to-use liquid forms have a pH of from about 2 to about 6 and include: (a) hydrogen peroxide in a concentration of from about 0.01 to about 4% w/w of the solution; (b) at least one surfactant chosen from imidazoline derivatives, alkyl betaines, alkyl amidopropyl betaine amides, alkyl amidopropyl betaines, alkylsulfo betaines, amine oxides and derivatives thereof in a concentration of from about 0.01 to about 15% w/w of the solution; (c) at least one hydrogen peroxide stabilizer in a concentration of from about 0.01 to about 4% w/w of the solution; (d) at least one member chosen from cyclic carboxylic acids and salts thereof in a concentration of from about 0.01 to about 4% w/w of the solution; and (e) at least one skin conditioning agent in a concentration of from about 0.01 to about 10% w/w of the solution.
Abstract: The present invention relates to the a bismuth-based composition, particularly involving the use of bismuth ions, particularly the Bi+3 ion, for prevention and/or treatment of the haemolytic uremic syndrome, with the invention also relating to the use of a bismuth ion in the manufacture of a medicament for the prevention and/or treatment of an infection caused by a Shiga-toxin producing Escherichia coli strain, as well as to a method for preventing and/or treating the haemolytic uremic syndrome comprising administering bismuth ions to a patient in need thereof, and a method for inhibiting dissemination of the gene encoding virulence factors of a Shiga-toxin producing Escherichia coli strain in animals and humans.
Abstract: Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.
Abstract: An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficulty soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, “Entrapped Drug Reservoir System”.
Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.
Abstract: The present invention relates to pharmaceutical compositions and methods useful for the treatment of dermatological disorders, and in particular acne vulgaris and skin pigmentation disorders. Pharmaceutical compositions comprising one or more arginine, salicylic acid and/or azelaic acid that are useful for the treatment of dermatological diseases and the symptoms and underlying causes of such dermatological diseases are also disclosed.
Type:
Application
Filed:
June 11, 2012
Publication date:
June 26, 2014
Applicant:
Evologie LLC
Inventors:
Gary I. Weinberger, H. Robert Nagel, Richard A. Browm
Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
Type:
Grant
Filed:
February 21, 2012
Date of Patent:
June 24, 2014
Assignee:
The Regents of the University of Oklahoma
Abstract: A powder comprising core/shell particles having an average particle size of less than 1000 microns, each particle comprising: 1) a liquid core that is substantially free of water and comprises a polar liquid having a percent surface polarity of at least 24%, and 2) a shell comprising hydrophobic particles, is provided.
Type:
Application
Filed:
January 8, 2014
Publication date:
June 19, 2014
Applicant:
Johnson & Johnson Consumer Companies, Inc.
Abstract: Methods for therapy of cystic fibrosis and other conditions are provided. The methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e. ABC transporters such as MDR-1 or MRP-2) in cells. Other embodiments include the use of agents to modulate transport of thiol-containing compounds within the cell. Therapeutic methods involve the administration of such agents to a patient afflicted with cystic fibrosis and/or another condition responsive to stimulation of thiol-containing compound transport.
Type:
Application
Filed:
February 13, 2014
Publication date:
June 12, 2014
Applicant:
NATIONAL JEWISH MEDICAL AND RESEARCH CENTER
Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
Type:
Grant
Filed:
March 22, 2012
Date of Patent:
May 27, 2014
Assignee:
Catabasis Pharmaceuticals, Inc.
Inventors:
Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.
Type:
Grant
Filed:
March 22, 2012
Date of Patent:
May 27, 2014
Assignee:
Catabasis Pharmaceuticals, Inc.
Inventors:
Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
Abstract: Described herein are novel methods for the treatment of rosacea which include the step of applying of a composition containing a polymetal complex to an area of the skin afflicted with rosacea and novel regimens using such compounds.
Type:
Application
Filed:
September 13, 2013
Publication date:
May 15, 2014
Inventors:
Joseph R. Faryniarz, Jose E. Ramirez, Hovig Ounanian
Abstract: The present application provides an aqueous, stable, VOC-free microemulsion based antimicrobial disinfectant and/or cleaning concentrate composition capable of inhibiting or killing gram(+), gram(?) and methicillin-resistant Staphylococcus aureus (MRSA) comprising (i) a water-soluble matrix composite made of (a) water-soluble polymer, and (b) water-soluble surfactant; (ii) a blend of antimicrobial agents comprising (a) at least one compound selected from phenols, halogenated phenols, derivatives of phenols, derivatives of halogenated phenols, bis -phenols, cresols, resorcinols, halogenated hydroxyl diphenylethers, anilides or combinations thereof; and (b) at least one compound derived from essential oils; and (iii) optionally, one or more additives. Also, there is described a method of use and process for preparing the composition.
Type:
Application
Filed:
June 8, 2012
Publication date:
May 15, 2014
Applicant:
ISP Investments Inc.
Inventors:
Kolazi S Narayanan, Domingo Jon, Patel V. Jayanti, Liu Xuejun, Karen Winkowski, Raman Premachandran, Lindstrom Susan
Abstract: Protein preparations containing biologically active compounds and the application of the protein preparations obtained, particularly as a component of medicinal and cosmetic preparations as protective substances or in the regeneration of cells and tissues of the human organism, and which can comprise a component of culture media for dermal or hepatic tissues, or for stem cells destined for use in the regeneration of cells and tissues in the human organism.
Type:
Grant
Filed:
November 20, 2007
Date of Patent:
May 6, 2014
Assignee:
Instytut Medycyny Doswiadczalnej I Klinicznej
Inventors:
Andrzej Lipkowski, Anna Grabowska, Katarzyna Kurzepa, Aleksandra Szczucinska
Abstract: At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.
Type:
Grant
Filed:
January 12, 2010
Date of Patent:
April 29, 2014
Assignee:
L'Oreal
Inventors:
David Amar, Bruno Bernard, Dominique Bernard, Isabelle Castiel
Abstract: Mixtures are described comprising two or more compounds selected from at least two of the following groups: i) salicylic acid and/or its functional analogous products (ESA), ii) promoting compounds (PRO) and iii) modulating compounds (MOD), and their use for stimulating the natural defense systems of plants and for inducing resistance in plants. The use is also described, of two or more compounds selected from at least two of the following groups: one or more compounds belonging to the ESA group and/or one or more compounds belonging to the PRO group and/or one or more compounds belonging to the MOD group, individually adopted by means of application programs which envisage alternating application, to stimulate the natural defense systems of plants and inducing resistance in plants.
Type:
Grant
Filed:
August 20, 2010
Date of Patent:
April 22, 2014
Assignee:
Isagro S.p.A.
Inventors:
Lucio Filippini, Marilena Gusmeroli, Silvia Mormile, Carlo Garavaglia, Luigi Mirenna
Abstract: Topical skin treatment formulation containing salicylic acid or a derivative thereof, dissolved in a solvent system comprising (i) dimethyl isosorbide; (ii) a C1 to C9 alkyl salicylate; and (iii) a glyceryl fatty acid ester. The solvent system may also comprise an alcohol, a polyoxyalkylene-based solvent, and/or a C1 to C4 alkyl glucose ester. The formulation may be used in the treatment of acne. The solvent system improves the targeted delivery of the salicylic acid or derivative to relevant sites on the skin.
Type:
Application
Filed:
March 26, 2012
Publication date:
April 17, 2014
Applicant:
EVOCUTIS PLC
Inventors:
Steven John Abbott, Jonathan Howard Cove, Gavin Donoghue, Sarah-Jayne Gregory
Abstract: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.
Type:
Application
Filed:
June 3, 2013
Publication date:
April 3, 2014
Inventors:
Upendra K. Marathi, Susann Edler Childress, Shaun L. Gammill, Robert W. Strozier
Abstract: The present invention relates to a water-absorbing particulate composition comprising water-absorbing polymer particulate structure comprising partly neutralized, crosslinked polyacrylate, a surface crosslinking agent and a compound of the structure I in which R1, R2, R3 and R4 can be identical or different and in each case represent a hydrogen atom, a halogen atom, a C1- to C4-hydrocarbon group or a hydroxyl group, R5 represents a hydrogen atom, a C1- to C4-hydrocarbon group or an acetyl group, n represents an integer chosen from the group consisting of 1, 2 or 3 and Mn+ represents an n-valent metal cation or an H+ cation. In addition, the present invention also relates to a process for the preparation of a water-absorbing composition, the water-absorbing composition obtainable by this process, a composite, a process for the production of a composite, the composite obtainable by this process, and products, such as hygiene articles.
Abstract: External preparations for treatment of painful skin wound having an analgesic activity which comprises acetylsalicylic acid or its pharmacologically acceptable salt as an active ingredient.
Abstract: The present invention relates to compositions including anhydrous compositions which include a dimethicone crosspolymer and/or dimethicone elastomer gum and one or more skin care products which may include retinoic acid, retinoic acid derivatives, retinal, retinol and/or retinyl esters, and methods of making, storing, and using such compositions.
Type:
Application
Filed:
August 7, 2013
Publication date:
January 16, 2014
Applicant:
Chemsil Silicones, Inc.
Inventors:
James Jefferies Harrison, Nohemi Harrison
Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
Type:
Grant
Filed:
November 28, 2012
Date of Patent:
January 14, 2014
Assignee:
The Regents of the University of Oklahoma
Abstract: The invention provides compositions and methods for treating or preventing cancer with an inventive composition. The invention relates to the fields of biomedicine, pharmacology, and molecular biology.
Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.
Type:
Grant
Filed:
May 3, 2012
Date of Patent:
January 7, 2014
Assignee:
The Regents of the University of Oklahoma
Abstract: The present invention provides novel aspirin derivatives useful for preventing and/or treating cancer. The novel compounds of this invention may be particularly useful for the prevention and/or treatment of cancers affecting the gastrointestinal system, such as colorectal cancer.
Abstract: The present invention relates to compositions, kits and methods for treating skin at sites of concerns such as infectious lesions and/or points of insertion of an insertable medical device to prevent contamination such as infections or protein absorption that may interfere with the function of the device. The composition can be a topical skin treatment composition that includes polyethylene glycol (PEG), triclosan, one or more of a salicylate, bronopol, and an acrylic emulsion, and, optionally, a solvent.
Abstract: The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry, and provides methods and compositions for treating sexual dysfunction; more particularly, the invention relates to treatment of premature ejaculation in humans.
Abstract: An orally disintegrating multilayer tablet comprising at least two discrete layers, one of which comprises at least one active agent that promotes the oxidation of opioids, preferably acetaminophen, and the other of which contains granules including an inert core which is coated with at least one opioid and at least one binder, wherein said opioid coating is coated with a subcoat comprising a compound soluble in gastric fluids, said subcoat being coated with a taste-masking coating comprising a polymer or copolymer comprising dialkylaminoalkyl(meth)acrylate units and a pore-forming agent.
Abstract: The present invention provides an environmentally compatible, pesticidal composition and method for the control of insect pests. The composition includes two components. The first component is a chelating agent, a metal complex of a chelating agent, and mixtures thereof, and the second component is preferably a carrier material.
Abstract: The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants.
Type:
Application
Filed:
March 14, 2013
Publication date:
October 24, 2013
Inventors:
Alec Mian, Luc Marti Clauzel, Eric Mayoux, Silvia Garcia Vicente, Marta Serrano Munoz, Antonio Zorzano Olarte
Abstract: A bimodal bioabsorbable polymer composition. The composition includes a first amount of a bioabsorbable polymer polymerized so as to have a first molecular weight distribution; a second amount of said bioabsorbable polymer polymerized so as to have a second molecular weight distribution having a weight average molecular weight between about 10,000 to about 50,000 Daltons, the weight average molecular weight ratio of said first molecular weight distribution to said second molecular weight distribution is at least about two to one; wherein a substantially homogeneous blend of said first and second amounts of said bioabsorbable polymer is formed in a ratio of between about 50/50 to about 95/5 weight/weight percent. Also disclosed are a medical device, a method of making a medical device and a method of melt blowing a semi-crystalline polymer blend.
Abstract: A method for treating a patient/subject having neuronal injury, pain, neurotrauma and/or traumatic brain injury, such as diffuse axonal injury, which includes intrathecally and/or intraventricularly administering to the subject a therapeutically effective amount of a non-steroidal anti-inflammatory drug and/or a naturally occurring omega conotoxin, functional fragment thereof, a pharmacologically acceptable salt, ester, amide, or prodrug thereof.
Abstract: Disclosed herein is a composition containing a high concentration of PG is unexpectedly capable of quickly killing other bacteria, fungi, and/or virus in vitro that is indicative of its potential high efficacy in treating various skin infection. Embodiments disclosed herein relate to a composition and method for effective topical treatment of inflammatory skin lesions in mammals, comprising of a high concentration of propylene glycol alone, or in combination with an astringent. The PG at high concentrations can be regarded as an extremely effective, safe, topical, universal, microbicide.
Abstract: Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.
Abstract: The solubility in solvent media, notably alcoholic media, of the beta-hydroxy acids (“BHAs”), notably the chemical skin peeling agent salicylic acid, is markedly enhanced by solubilizing same in the presence of at least one alpha-hydroxy acid (“AHA”); higher potency, more concentrated BHA skin peel products are thus formulated.
Type:
Grant
Filed:
February 26, 2003
Date of Patent:
July 23, 2013
Assignee:
Societe L'Oreal S.A.
Inventors:
Marc Cornell, Hani Fares, Sidney Peter Foltis, Isabelle Hansenne
Abstract: Catheters used for medical treatment, e.g., hemodialysis are filled with a locking solution, usually heparin between treatments. To prevent infections, antimicrobial or antibiotic substances have been used as locking solution alone or in combination with antithrombotic substances. It has been found that these locking solutions are rapidly washed out from the catheter tip. The invention describes a thixotropic gel that can be used as locking solution. Beneficial, substances, e.g., antimicrobial or antibiotic substances can be added to the gel. A preferred antimicrobial substance is taurolidin alone or in combination with salicylic acid or one of its salts.
Abstract: This disclosure relates to a pharmaceutical composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5?-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that is a serotonin metabolite.
Abstract: Disposable absorbent articles comprising an absorbent material and an antimicrobial composition are disclosed. The antimicrobial composition includes a carrier comprising fatty alcohol and a poly(alkyleneoxy) polymer, and an antimicrobial agent. The antimicrobial composition may be coated on to component substrates such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, wound dressings, bandages, panty liners and tampons, personal care wipes and household wipes to provide odor control, and control of microbial growth.
Type:
Application
Filed:
September 13, 2011
Publication date:
June 27, 2013
Inventors:
David T. Amos, Bathsheba E. Chong Conklin, Alexis S. Statham, Michael J. Svarovsky, Leigh E. Wood
Abstract: Eudermic composition comprising at least one eudermically active principle, at least one vehicle for said active principle, and porous silica particles, wherein the active principle is contained in at least one pore of at least a first portion of such silica particles and in the vehicle.
Abstract: The present invention relates to TRPV1 selective agonist topical compositions including capsaicinoid and analgesic agent compositions and methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.
Abstract: This invention relates to methods for reducing chronic subacute inflammatory states associated with obesity and improve glycemia, thereby preventing or delaying the development of type 2 diabetes (T2D) in obese subjects, or subjects with the metabolic syndrome, using non-acetylated forms of salicylate, e.g., salsalate or trilisate.
Abstract: The present invention relates to compounds, intermediates used in the preparation of such compounds, processes for the preparation of such compounds of the formula VI and formula VII and such intermediates, pharmaceutical compositions comprising such compounds of the formula VI and such compounds of the formula VII, and the uses of such compounds of the formula VI and such compounds of the formula VII as antidiabetic, pre-antidiabetic, antiobesity and cardioprotective agents.
Abstract: The present invention relates to a mesalamine rectal suppository designed to provide improved comfort of use. One embodiment of the invention is a mesalamine rectal suppository comprising mesalamine and one or more pharmaceutically acceptable excipients, wherein the drug load of the suppository ranges from 35% to 50%. Yet another embodiment of the invention is a mesalamine rectal suppository comprising mesalamine having a tap density ranging from about 600 to about 800 g/L (as measured by USP <616>) and a hard fat having an ascending melting point of 32 to 35.5° C. Yet another embodiment is a mesalamine rectal suppository comprising mesalamine particles and one or more pharmaceutically acceptable excipients, where the mesalamine particles have a surface area of from about 0.1 m2/g to about 2.8 m2/g (e.g., from about 0.1 m2/g to about 1.3 m2/g). Methods of preparing and methods of treatment with mesalamine suppositories are also provided.
Type:
Grant
Filed:
December 16, 2009
Date of Patent:
May 7, 2013
Assignee:
Aptalis Pharma Canada Inc.
Inventors:
Carl Gauthier, Yves Dumoulin, David Powell, Hugues Moreau
Abstract: Disclosed is a method for reducing the appearance of a fine line or wrinkle on skin comprising topically applying to said fine line or wrinkle a composition comprising a glyceryl di-salicylate compound having the following structure: wherein the composition further includes a glyceryl mono-salicylate compound, and wherein the composition reduces the appearance of said fine line or wrinkle on skin.
Abstract: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.
Abstract: Methods for prevention or treatment of capsular contracture following surgical implants and other fibrosis related conditions comprising applying a topical composition comprising a pharmaceutically acceptable keratolytic, a pharmaceutically acceptable protein denaturant, a hydrating agent, and combinations thereof are disclosed.
Abstract: Conjugates comprising at least two active agents linked by a diglycolic acid or polyglycol diacid linker are disclosed. The invention also concerns oligomers and polymers of these conjugates and their use in therapeutic and industrial applications for localized, immediate or fast release delivery of an active agent, such as an anti-microbial, anti-infective, or antiseptic agent.
Type:
Application
Filed:
May 9, 2012
Publication date:
March 21, 2013
Inventors:
Suseela Kanamathareddy, Karen J. Giroux
Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.
Type:
Application
Filed:
May 4, 2011
Publication date:
February 28, 2013
Applicant:
FOAMIX LTD.
Inventors:
Dov Tamarkin, Elana Gazal, Yohan Hazot, David Schuz
Abstract: Provided is a bone-transplant or bone-filling composition, which comprises a dihydroxybenzoic acid derivative which has been newly demonstrated to increase the activity of osteoblasts and so induce bone formation.